GlassScriptPhysician profile
Allyson M Ray
NPI 1215026497
$2,256.43
in general payments reported to CMS, 2019-2025
13 companies · $155 in 2025
The $155 reported for 2025 was less than what a typical Plastic Surgery Within The Head & Neck provider received nationally (typical 2025 total: $238).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $49.45 · 2020: $16.54 · 2021: $15.17 · 2022: $43.49 · 2023: $274 · 2024: $1,703 · 2025: $155.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Travel and Lodging: $1,258 · Food and Beverage: $874.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Travel and Lodging | $1,258.11 |
| Food and Beverage | $873.67 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $1,673.13 | 2021-2025 | Quadcut, Sinuva, Fusion |
| Genzyme Corporation | $172.24 | 2023-2025 | |
| Glaxosmithkline, LLC. | $160.71 | 2023-2025 | Nucala |
| Acclarent, INC | $43.63 | 2022-2024 | Acclarent Aera |
| Aerin Medical INC. | $36.56 | 2019-2023 | |
| Integra Lifesciences Corporation | $31.66 | 2022-2023 | Microfrance, Codman Isocool Aht, Integra Duo |
| Inspire Medical Systems, INC. | $30.34 | 2024 | Inspire |
| Optinose US, INC. | $27.52 | 2024 | |
| Circassia INC. | $17.78 | 2019 | |
| Intersect Ent, INC. | $16.54 | 2020 | |
| Olympus America INC. | $16.21 | 2024 | Rhino-Laryngo Videoscope |
| Astrazeneca Pharmaceuticals LP | $15.15 | 2025 | Tezspire |
| Covidien LP | $14.96 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Allyson Ray listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.